Navigation Links
JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells

NEW YORK, February 4, 2008 The Juvenile Diabetes Research Foundation (JDRF), the worlds largest charitable funder of type 1 diabetes research, announced today that it is partnering with Plureon Corporation, a biotechnology company based in Winston-Salem, N.C. that focuses on developing therapeutic applications of stem cells.

Through its Industry Discovery and Development Partnership Program, JDRF is providing $500,000 over two years of research funding aimed at developing an insulin-producing beta cell therapy product for the treatment of type 1 diabetes.

Plureon is exploring exciting alternatives to treat or cure diabetes by developing cell therapies to replace beta cells using adult stem cells as a source, said Julia Greenstein, Therapeutic Program Director for Replacement at JDRF. The results from this study may provide a new strategy to restore function of insulin-producing cells, creating a significant, positive clinical impact on patients with diabetes.

This award enables us to extend our research in the field of diabetes, said Hal Eason, founder and CEO of Plureon. By leveraging our existing technology and know-how across additional sources of stem cells, we hope to open new pathways towards a cure. We are grateful for JDRFs partnership in this pursuit.

The project plans to use Plureons technology platform to isolate adult stem cells from a type 1 diabetes patient and re-program them to generate fully functional pancreatic beta-cells. The objective is to return the re-programmed insulin-producing cells back into the patient in an autologous manner, i.e., without the need for immunosuppressive agents normally required for organ transplantation in this manner, the patients own transplanted cells will be capable of glucose-dependent insulin secretion and the restoration of normal blood sugar levels.

Plureon is the latest company to work with JDRF through its innovative Industry Discovery and Development Partnership program. Through the program, JDRF partners with pharmaceutical, biotech, and medical device businesses that seek to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications. To date, JDRF has 22 IDDP partners across a range of research areas, committing approximately $25 million in research funding.

Diabetes is a chronic, debilitating disease affecting every organ system. There are two major types of diabetes: type 1 and type 2. Type 1 diabetes is an autoimmune disease in which a persons pancreas stops producing insulin, a hormone that enables people to get energy from food. Type 1 diabetes usually strikes in childhood, adolescence, or young adulthood, but lasts a lifetime. People with type 1 diabetes must take multiple injections of insulin daily or continuous infusion of insulin through a pump just to survive. (Type 2 diabetes is a metabolic disorder in which a persons body still produces insulin but is unable to use it effectively.) Taking insulin does not cure any type of diabetes nor prevent the possibility of its eventual and devastating effects: kidney failure, blindness, nerve damage, amputation, heart attack, and stroke.


Contact: Susan Sherman
Juvenile Diabetes Research Foundation International

Related medicine news :

1. Sergeants(R) Pet Care Products Announces Cause Marketing Partnership With the National Wildlife Federation
2. Red Cross Partners with YeePay on China Snow Disaster Relief
3. Bobbi Brown Cosmetics Creates Limited-Edition Lip Palette in Partnership with The Heart Truths Red Dress Collection 2008 Fashion Show
4. HealthPartners Contracts with SEIU Healthcare Minnesota Expires with No Agreement on New Contracts
5. Bobbi Brown Cosmetics Creates Limited-Edition Red Lip Palette in Partnership With The Heart Truths 2008 Red Dress Collection
6. Helios Education Foundation Invests $6.5 Million in New Partnership with TGen
7. Abbey Spanier Rodd & Abrams, LLP Files Class Action Lawsuit on Behalf of Purchasers of American Dental Partners, Inc. Securities
8. MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers
9. Time Domain Adds Eleven Partners to its Channel Reseller Network of PLUS(TM) Ultra Wideband Solutions Providers
10. Arthur Patrick Partners Acquires Fit Fuel, LLC
11. Medical University of South Carolina (MUSC) and Halsey Institute Create Partnership Between Art and Science
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- A large study of patients with breast cancer who ... found no increased risk of recurrence. The Kaiser Permanente ... National Cancer Institute. --> ... drug taken by women with breast cancer to reduce ... for five years, but has notable side effects, including ...
(Date:12/1/2015)... BOTHELL Wash. and VANCOUVER ... Monitoring Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... trial is continuing based on the pre-planned interim futility ... safety review, no new safety issues were identified by ... to all analyses and final results are expected in ...
(Date:12/1/2015)... HERNDON, Va. , Dec. 1, 2015 ... (FDA) Drug Supply Chain Security Act (DSCSA) approaches, ... helping small and independent pharmacies comply with looming ... --> InfiniTrak is entering endorsement agreements with ... a pharmacy services administration organization (PSAO) to exclusively ...
Breaking Medicine Technology: